Trials / Recruiting
RecruitingNCT05000554
The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First Hospital of Jilin University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety and efficacy of local advanced stomach cancer patients receiving new complementary treatment of PD-1 monoantiotherapy before surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Neoadjuvant Therapy | Drug: Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa\<1.25m2,40mg/time，twice a day；bsa1.25\~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14； Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection |
Timeline
- Start date
- 2021-07-02
- Primary completion
- 2026-03-01
- Completion
- 2026-06-01
- First posted
- 2021-08-11
- Last updated
- 2021-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05000554. Inclusion in this directory is not an endorsement.